Your browser doesn't support javascript.
Can Epigenetics Help Solve the Puzzle Between Concomitant Cardiovascular Injury and Severity of Coronavirus Disease 2019?
Braga, Cássia L; Acquarone, Mariana; Arona, Victor da C; Osório, Brenno S; Barreto, Thiago G; Kian, Ruan M; Pereira, João P A L; Silva, Marina de Moraes C da; Silva, Bagnólia A; de Oliveira, Gláucia Maria M; Macedo Rocco, Patricia Rieken; Silva, Pedro Leme; Alencar, Allan K N.
  • Braga CL; Laboratório de Investigação Pulmonar, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Acquarone M; Faculdade de Medicina de Petrópolis, School Clinic, Petrópolis, Brazil.
  • Arona VDC; Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Osório BS; Faculdade de Medicina de Petrópolis, School Clinic, Petrópolis, Brazil.
  • Barreto TG; Faculdade de Medicina de Petrópolis, School Clinic, Petrópolis, Brazil.
  • Kian RM; Faculdade de Medicina de Petrópolis, School Clinic, Petrópolis, Brazil.
  • Pereira JPAL; Faculdade de Medicina de Petrópolis, School Clinic, Petrópolis, Brazil.
  • Silva MMCD; Faculdade de Medicina de Petrópolis, School Clinic, Petrópolis, Brazil.
  • Silva BA; Serviço de Radiologia do Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • de Oliveira GMM; Programa de Pós-graduação em Produtos Naturais e Sintéticos Bioativos, Departamento de Ciências Farmacêuticas, Universidade Federal da Paraíba, João Pessoa, Brazil.
  • Macedo Rocco PR; Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; and.
  • Silva PL; Laboratório de Investigação Pulmonar, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Alencar AKN; Laboratório de Investigação Pulmonar, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
J Cardiovasc Pharmacol ; 79(4): 431-443, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-1778958
ABSTRACT
ABSTRACT The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has significant implications in patients with concomitant cardiovascular disease (CVD) because they are the population at the greatest risk of death. The treatment of such patients and complications may represent a new challenge for the fields of cardiology and pharmacology. Thus, understanding the involvement of this viral infection in CVD might help to reduce the aggressiveness of SARS-CoV-2 in causing multiorgan infection and damage. SARS-CoV-2 disturbs the host epigenome and several epigenetic processes involved in the pathophysiology of COVID-19 that can directly affect the function and structure of the cardiovascular system (CVS). Hence, it would be relevant to identify epigenetic alterations that directly impact CVS physiology after SARS-CoV-2 infection. This could contribute to the view of this virus-induced CVS injury and direct forthcoming tackles for COVID-19 treatment to reduce mortality in patients with CVD. Targeting epigenetic marks could offer strong evidence for the development of novel antiviral therapies, especially in the context of COVID-19-related CVS damage. In this review, we address some of the main signaling pathways that are currently known as being involved in COVID-19 pathophysiology and the importance of this glint on epigenetics and some of its modifiers (epidrugs) to control the unregulated epitope activity in the context of SARS-CoV-2 infection, COVID-19, and underlying CVD.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Cardiovasc Pharmacol Year: 2022 Document Type: Article Affiliation country: FJC.0000000000001201

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Cardiovasc Pharmacol Year: 2022 Document Type: Article Affiliation country: FJC.0000000000001201